Navigation Links
Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012

RIDGEFIELD, Conn., May 16, 2012 /PRNewswire/ -- Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.  LUX-Lung 3, which compares the investigational oral, once-daily therapy, afatinib, to pemetrexed/cisplatin, is the largest Phase III trial to date in first-line EGFR mutation-positive, advanced, metastatic NSCLC patients, and the first to use pemetrexed/cisplatin as a comparator in this population.

The presentation of the LUX-Lung 3 trial will shed light on a distinct and specific NSCLC patient population, those with EGFR mutations.  EGFR mutations occur in 10 to 15 percent of NSCLC patients, and are well-established predictive biomarkers that provide specific targets for therapeutic intervention in NSCLC.  TitleLead AuthorPresentation detailsLUX-Lung 3: A randomized,
open-label, phase III study of
afatinib versus pemetrexed and
cisplatin as first-line treatment for
patients with advanced
adenocarcinoma of the lung
harboring EGFR-activating mutations.


James Chih-Hsin Yang, MD, PhD




Oral Abstract #LBA7500

Date: Monday, June 4
Time: 3:00 PM-3:15 PM CDT



 "We are excited to share the results of our pivotal LUX-Lung 3 trial, the largest and most robust ever conducted in EGFR mutation-positive patients," said Berthold Greifenberg, M.D., Vice President, Clinical Development and Medical Affairs, Oncology, Boehringer Ingelheim Pharmaceuticals, Inc.  "We are continuously advancing the development of our oncology pipeline and look forward to opportunities to contribute to the body of scientific knowledge in this area."

Additional Presentations of Boehringer Ingelheim Investigational CompoundsIn addition to the LUX-Lung 3 presentation, more than 15 studies of Boehringer Ingelheim's investigational therapies have been selected for inclusion at ASCO, demonstrating the company's innovative clinical development program across a variety of cancer types.Select Poster PresentationsTitleLead AuthorPoster detailsAfatinibLUX-breast 3: Randomized phase II study of
afatinib alone or with vinorelbine versus
investigator's choice of treatment in patients (pts)
with HER2-positive breast cancer (BC) with
progressive brain metastases (BM) after
trastuzumab or lapatinib-based therapy.

Heikki Joensuu, MD, Professor




Abstract #TPS647

Poster #15B

Date: Saturday, June 2
Time: 8:00 AM - 12:00 PM CDT


 LUX-breast 1: Randomized, phase III trial of
afatinib and vinorelbine versus trastuzumab and
vinorelbine in patients with HER2-overexpressing
metastatic breast cancer (MBC) failing one prior
trastuzumab treatment.

Nadia Harbeck, MD, PhD




Abstract #TPS649

Poster #15D

Date: Saturday, June 2
Time: 8:00 AM - 12:00 PM CDT

 LUX-breast 2: Phase II, open-label study of oral
afatinib in HER2-overexpressing metastatic breast
cancer (MBC) patients (pts) who progressed on
prior trastuzumab (T) and/or lapatanib (L).

Tamas Hickish, MD




Abstract # TPS651

Poster #15F

Date: Saturday, June 2
Time: 8:00 AM - 12:00 PM CDTLUX-head and neck 1: A phase III, randomized
trial of afatinib versus methotrexate (MTX) in
patients (pts) with recurrent/metastatic (R/M)
head and neck squamous cell carcinoma (HNSCC)
who progressed after platinum-based therapy.

Jean-Pascal H. Machiels, MD, PhD




Abstract # PS5598

Poster #32H

Date: Saturday, June 2

Time: 1:15 – 5:15 PM CDTLUX-head and neck 2: A randomized, double-
blind, placebo-controlled, phase III study of
afatinib as adjuvant therapy after chemoradiation
in primarily unresected, clinically high-risk, head
and neck cancer patients.

Barbara Burtness, MD




Abstract # TPS5599

Poster # 33A

Date: Saturday, June 2

Time: 1:15 – 5:15 PM CDTNintedanibTRICC-c: BIBF 1120 versus placebo in patients
receiving oxaliplatin plus fluorouracil and
leucovorin (mFOLFOX6) for advanced,
chemorefractory metastatic colorectal cancer
(mCRC)—A multicenter, randomized phase II trial
in progress.

Andreas Berger, MD




Abstract # TPS3636

Poster # 39A

Date: Monday, June 4
Time: 8:00 AM - 12:00 PM CDTVolasertibPhase I trial of the polo-like kinase (Plk) inhibitor
volasertib (BI 6727) combined with cisplatin or
carboplatin in patients with advanced solid

Herlinde Dumez




Abstract # 3018

Poster #10

Date: Saturday, June 2

Time: 1:15 – 5:15 PM CDTAbout Lung CancerLung cancer is the second most common cancer and kills more people than any other cancer.  In 2012, approximately 226,160 new cases of lung cancer will be diagnosed in the United States, with 160,340 Americans dying from the disease.
NSCLC is the most common form, accounting for about 85 percent of all lung cancers.[1]  Lung cancer remains an area of high unmet need, especially in its advanced stages where it is particularly aggressive and patients have limited treatment options.

About AfatinibAfatinib is an investigational compound.  Afatinib is not approved by the FDA; its safety and efficacy have not been established. 

Afatinib is an investigational oral, once-daily irreversible ErbB Family Blocker that specifically inhibits epidermal growth factor receptor (EGFR or ErbB1), human epidermal receptor 2 (HER2 or ErbB2), ErbB3 and ErbB4.  It is currently in phase III clinical development in NSCLC, head and neck and breast cancer. 

About the Afatinib Clinical Trial Program in Advanced NSCLCThe LUX-Lung studies evaluate the use of afatinib in various settings of advanced NSCLC, including in patients harboring EGFR mutations and those with recurrent disease.  These trials include:

  • LUX-Lung 1, a Phase IIb/III trial investigating afatinib plus best supportive care (BSC) versus placebo plus BSC in NSCLC patients who were previously treated with first-line chemotherapy and the reversible EGFR TKIs erlotinib or gefitinib.
  • LUX-Lung 2, a Phase II trial evaluating afatinib in NSCLC patients with EGFR mutations (EGFR M+), either treatment-naive or after one line of treatment with chemotherapy.
  • LUX-Lung 3, a Phase III trial investigating afatinib as a first-line treatment in patients with advanced NSCLC with EGFR mutations. 
  • LUX-Lung 4, a Phase I/II trial of afatinib in NSCLC patients who have progressed after conventional EGFR-TKI treatment. 
  • LUX-Lung 5, a global Phase III trial in patients previously treated with erlotinib or gefitinib. This is the first randomized Phase III trial investigating whether patients who initially benefit from treatment with afatinib alone may further benefit from afatinib beyond progression when given in combination with chemotherapy.
  • LUX-Lung 6, a Phase III trial investigating the efficacy and safety of afatinib compared to standard chemotherapy for first-line treatment of NSCLC patients with EGFR mutations.
  • LUX-Lung 7, a Phase IIb trial evaluating afatinib head-to-head versus gefitinib as a first-line treatment in EGFR M+ NSCLC patients.  Patient recruitment for this trial has recently initiated.
  • LUX-Lung 8, a Phase III trial evaluating afatinib head-to-head versus erlotinib in second-line treatment of squamous cell carcinoma of the lung.  Patient recruitment for this trial has recently initiated.
  • For more information on these trials, please visit

    About Boehringer Ingelheim in OncologyBuilding on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to develop innovative cancer treatments. Working in close collaboration with the international scientific community and a number of the world's leading cancer centers, Boehringer Ingelheim's commitment to oncology is underpinned by using advances in science to develop a range of targeted therapies for various solid tumors and hematological cancers.

    The current focus of late-stage research includes compounds in three areas: signal transduction inhibition, angiogenesis inhibition and cell-cycle kinase inhibition.  Afatinib is an investigational orally-administered irreversible inhibitor of the ErbB family of receptor tyrosine kinases, which is currently in phase III clinical development in advanced NSCLC, head and neck cancer, and breast cancer.  Nintedanib (BIBF 1120) is an investigational orally-administered triple angiokinase inhibitor that targets three of the receptor tyrosine kinases shown to aid in the regulation of angiogenesis and is currently in phase III clinical development in NSCLC and ovarian cancer.  Volasertib is an investigational inhibitor of polo-like kinase that is currently being investigated in early phase trials.  Boehringer Ingelheim's oncology pipeline continues to evolve and demonstrates the company's continued commitment to the disease area.

    For information about participating in a Boehringer Ingelheim clinical trial, please visit or call 1.866.725.7110.  Healthcare providers interested in learning more about Boehringer Ingelheim clinical trials in oncology can visit for additional information. 

    About Boehringer Ingelheim Pharmaceuticals, Inc.Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

    The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees.  Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

    As a central element of its culture, Boehringer Ingelheim has a demonstrated commitment to corporate social responsibility.  Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations.  Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

    In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion (13.2 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

    For more information, please visit and follow us on Twitter at

    References[1] American Cancer Society.  Cancer Facts and Figures: 2012.  Available at:  Last accessed April 27, 2012.


    SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
    2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
    3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
    4. Boehringer Ingelheim Unveils Diabetes Pipeline
    5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
    6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
    7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
    8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
    9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
    10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
    11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
    Post Your Comments:
    (Date:3/29/2017)... /PRNewswire/ - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a specialty ... year ended December 31, 2016 after market close ... being released later than the previous fiscal year,s ... operations and balances of Apicore from the acquisition ... filing date meets TSX Venture Exchange listed company ...
    (Date:3/28/2017)... 28, 2017 The global emerging cancer diagnostics ... 13.45% from 2016 to 2023 and reach a figure ... Cancer is a chronic disease and is affecting a ... diagnostics market. This report is focused on emerging cancer ... growth is propelled due to factors such as: increasing ...
    (Date:3/28/2017)... SPRING, Md. , March 28, 2017 /PRNewswire-USNewswire/ ... approved Dupixent (dupilumab) injection to treat adults with ... patients whose eczema is not controlled adequately by ... are not advisable. Dupixent can be used with ... of Dupixent demonstrates our commitment to approving new ...
    Breaking Medicine Technology:
    (Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... VisualSP has ... sustainably. Until recently, the only option for on-premises installation of its Help System for ... required to install the system into the entire tenant. , The company recently ...
    (Date:3/28/2017)... ... March 28, 2017 , ... India’s Chigurupati Technologies announced ... address the resolution to globally reduce the harmful use of alcohol set forth ... and TTB approved ingredients that when infused into alcohol, renders the alcohol liver ...
    (Date:3/28/2017)... ... 29, 2017 , ... The Thyroid Secret is a specialized ... The program was recently launched on March 1, and Dr. Wentz discussed varied ... , Dr. Izabella Wentz is a licensed pharmacist and a foremost thyroid specialist. ...
    (Date:3/28/2017)... ... March 28, 2017 , ... ... the science and clinical practice of radiosurgery, announced today the publication of ... observational registry established to standardize data collection from patients treated with stereotactic ...
    (Date:3/28/2017)... ... March 28, 2017 , ... WHO: , Dr. Paul Thomas; Dr. ... , Medical doctors and PhD scientists will speak to the press on behalf of ... support of an independent vaccine safety commission. , WHERE: , Zenger Room, National ...
    Breaking Medicine News(10 mins):